Omeros Corporation (NASDAQ:OMER) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Moderate Buy consensus: Six brokerages give Omeros a consensus rating of "Moderate Buy," with an average 12‑month target price of $40.33.
• Mixed fundamentals: The company reported a quarterly EPS of $3.14 vs. a -$0.55 consensus, yet analysts still forecast -1.54 EPS for the fiscal year; shares trade around $14.83 with a market cap of about $1.07 billion.
• Diverging analyst and institutional activity: HC Wainwright raised its price target to $40 and Zacks upgraded to strong‑buy while Weiss maintained a sell rating, and institutional ownership is roughly 48.8% with JPMorgan markedly increasing its stake.

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $40.3333.

A number of brokerages have recently issued reports on OMER. HC Wainwright upped their price objective on Omeros from $20.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, January 8th. Wall Street Zen cut Omeros from a "buy" rating to a "hold" rating in a research note on Sunday, April 26th. Zacks Research upgraded Omeros from a "hold" rating to a "strong-buy" rating in a research note on Thursday, April 2nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Omeros in a research note on Tuesday, April 21st. Finally, D. Boral Capital reiterated a "buy" rating and set a $36.00 price objective on shares of Omeros in a research note on Tuesday, April 21st.

Omeros Trading Up 0.4%

Omeros stock opened at $14.83 on Thursday. The firm has a market capitalization of $1.07 billion, a P/E ratio of -29.66 and a beta of 2.66. Omeros has a 1 year low of $2.95 and a 1 year high of $17.65. The business has a 50-day moving average of $11.94 and a 200-day moving average of $11.12.

Omeros (NASDAQ:OMER - Get Free Report) last posted its earnings results on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $3.69. Research analysts anticipate that Omeros will post -1.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in OMER. JPMorgan Chase & Co. increased its holdings in shares of Omeros by 1,201.1% during the third quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company's stock valued at $1,706,000 after acquiring an additional 384,168 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Omeros by 86.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,929 shares of the biopharmaceutical company's stock valued at $90,000 after acquiring an additional 10,161 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Omeros by 7.1% during the third quarter. Rhumbline Advisers now owns 105,873 shares of the biopharmaceutical company's stock valued at $434,000 after acquiring an additional 7,048 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Omeros by 11.2% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 29,097 shares of the biopharmaceutical company's stock valued at $129,000 after acquiring an additional 2,941 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of Omeros by 99.7% during the third quarter. SG Americas Securities LLC now owns 45,324 shares of the biopharmaceutical company's stock valued at $186,000 after acquiring an additional 22,623 shares in the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.